Sun Pharmaceutical Industries Ltd and Bayer have signed an agreement to market and distribute a second brand of finerenone in the country. Bayer has granted non-exclusive rights to Sun Pharma to market and distribute a second brand of finerenone named Lyvelsa.Kirti Ganorkar, CEO of India Business at Sun Pharma, said, “We are happy to collaborate with Bayer to provide patients access to a new treatment which slows down the progression of chronic kidney disease and reduces the risk of kidney failure associated with Type-2 diabetes. This partnership underscores our commitment to make innovative medicines available to patients in India.” Shweta Rai, Country Division Head (CDH) for Bayer’s Pharmaceuticals Business in South Asia, said, “With the introduction of a second brand of finerenone in India, through our partnership with Sun Pharma, we are advancing Bayer’s commitment of making healthcare accessible to as many patients as possible.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!